Setmelanotide (IMCIVREE): Side Effects
Known side effects, contraindications, and interactions
๐TL;DR
- โข6 known side effects documented
- โข3 mild, 2 moderate, 1 severe
- โข3 contraindications listed
Compare side effects across multiple peptides โ
Side Effects Severity Chart
Darkening of the skin is observed in the majority of setmelanotide- treated patients due to cross-reactivity with MC1R on melanocytes. Generally diffuse and dose-dependent. Usually reversible upon discontinuation. Skin exams are recommended before starting and during treatment.
Local reactions at the injection site including erythema, pain, and induration. Generally mild and self-limiting.
Spontaneous penile erections have been reported in male patients, including pediatric patients. This is a pharmacological effect of MC4R activation. Part of the REMS program monitoring requirement.
Sexual adverse reactions including disturbances in sexual arousal have been reported in both male and female patients. The REMS program includes specific counseling requirements for these events.
Depression and suicidal ideation have been reported in patients treated with setmelanotide. Patients should be monitored for new or worsening depression and suicidal thoughts.
Abdominal pain and gastrointestinal discomfort have been reported in clinical trials at moderate frequency.
โContraindications
- โขNot for use in patients without confirmed genetic variants in POMC, PCSK1, LEPR, or Bardet-Biedl syndrome genes
- โขNot recommended during pregnancy; weight loss is not beneficial during pregnancy
- โขHypersensitivity to setmelanotide or any component of the formulation
โ ๏ธDrug Interactions
- โขNo formal drug interaction studies have been conducted due to the rare disease population
- โขUse caution with drugs that may increase risk of depression or suicidal ideation
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 15+ community reports
View community protocolsSafety Overview#
Setmelanotide's safety profile reflects its pharmacological mechanism as a melanocortin receptor agonist. The most characteristic side effects are skin hyperpigmentation (from MC1R cross-reactivity) and sexual adverse events (from MC4R effects on sexual function). The drug is distributed through a REMS program that addresses these specific risks.
Skin Hyperpigmentation#
The most common side effect of setmelanotide is skin hyperpigmentation, observed in the majority of treated patients. This is a direct pharmacological consequence of MC1R activation on melanocytes:
- Mechanism: MC1R agonism stimulates melanin production in melanocytes
- Presentation: Usually diffuse, dose-dependent skin darkening
- Reversibility: Generally reversible upon discontinuation
- Monitoring: Baseline and periodic skin examinations are recommended
- Preexisting nevi: Patients should be monitored for changes in existing moles or skin lesions
Sexual Adverse Events#
Sexual adverse reactions are a notable safety concern that led to the REMS program:
- Spontaneous penile erections: Reported in male patients, including pediatric patients
- Sexual arousal disturbances: Reported in both males and females
- MC4R mechanism: MC4R is expressed in brain regions involved in sexual function
- REMS requirement: Healthcare providers must counsel patients about these risks before treatment
Depression and Suicidal Ideation#
Depression and suicidal ideation have been reported with setmelanotide. While the causal relationship is not fully established, patients should be monitored for mood changes:
- Monitor for new or worsening depression
- Monitor for suicidal thoughts or behaviors
- Consider risk-benefit in patients with preexisting mood disorders
Injection-Site Reactions#
Local reactions at the injection site are common but generally mild and self-limiting. Rotating injection sites helps mitigate local irritation.
Summary of Adverse Events from Clinical Trials#
| Adverse Event | Frequency | Severity |
|---|---|---|
| Skin hyperpigmentation | Very common (>50%) | Mild |
| Injection-site reactions | Very common | Mild |
| Spontaneous erections (males) | Common | Moderate |
| Sexual adverse reactions | Common | Moderate |
| Abdominal pain | Common | Mild |
| Depression | Uncommon | Severe |
Safety Profile Context#
Setmelanotide (IMCIVREE) belongs to the Metabolic category of research peptides. Understanding the side effect profile of Setmelanotide (IMCIVREE) is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.
Reported Side Effects#
The following side effects have been documented in clinical studies of Setmelanotide (IMCIVREE). Side effect severity and frequency are based on available clinical data.
Skin Hyperpigmentation#
Severity: mild | Frequency: very-common
Darkening of the skin is observed in the majority of setmelanotide- treated patients due to cross-reactivity with MC1R on melanocytes. Generally diffuse and dose-dependent. Usually reversible upon discontinuation. Skin exams are recommended before starting and during treatment.
Injection-Site Reactions#
Severity: mild | Frequency: very-common
Local reactions at the injection site including erythema, pain, and induration. Generally mild and self-limiting.
Spontaneous Penile Erections#
Severity: moderate | Frequency: common
Spontaneous penile erections have been reported in male patients, including pediatric patients. This is a pharmacological effect of MC4R activation. Part of the REMS program monitoring requirement.
Sexual Adverse Reactions#
Severity: moderate | Frequency: common
Sexual adverse reactions including disturbances in sexual arousal have been reported in both male and female patients. The REMS program includes specific counseling requirements for these events.
Depression and Suicidal Ideation#
Severity: severe | Frequency: uncommon
Depression and suicidal ideation have been reported in patients treated with setmelanotide. Patients should be monitored for new or worsening depression and suicidal thoughts.
Abdominal Pain#
Severity: mild | Frequency: common
Abdominal pain and gastrointestinal discomfort have been reported in clinical trials at moderate frequency.
Contraindications#
The following contraindications have been identified for Setmelanotide (IMCIVREE) based on available research and pharmacological considerations:
- Not for use in patients without confirmed genetic variants in POMC, PCSK1, LEPR, or Bardet-Biedl syndrome genes
- Not recommended during pregnancy; weight loss is not beneficial during pregnancy
- Hypersensitivity to setmelanotide or any component of the formulation
Individuals with any of these conditions should not use Setmelanotide (IMCIVREE) without consulting a qualified healthcare provider.
Drug Interactions#
The following potential drug interactions have been identified for Setmelanotide (IMCIVREE):
- No formal drug interaction studies have been conducted due to the rare disease population
- Use caution with drugs that may increase risk of depression or suicidal ideation
Drug interaction studies for Setmelanotide (IMCIVREE) remain limited. Researchers should exercise caution when combining Setmelanotide (IMCIVREE) with other compounds and consult relevant pharmacological references.
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Setmelanotide (IMCIVREE)
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.